Research programme: hepatitis B antivirals - Pharmasset

Drug Profile

Research programme: hepatitis B antivirals - Pharmasset

Alternative Names: Hepatitis B antivirals - Pharmasset; L-3'-FD4C; β-L-3'-Fluoro-2',3'-didehydro-2,3'-dideoxycytidine

Latest Information Update: 29 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emory University; Pharmasset
  • Class
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 29 Sep 2003 Preclinical trials in Hepatitis B treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top